Telix and Cyclotek Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand
Melbourne (Australia) – 31 July 2017. Telix Pharmaceuticals and Cyclotek conclude a radiopharmaceutical manufacturing agreement for Australia and New Zealand.
Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd (Cyclotek).
Under the agreement, Cyclotek will provide Telix with radiopharmaceutical manufacturing and distribution services for Telix’s pipeline of oncology products, for both clinical trial purposes and, where appropriate, prescriber exemption use.
Telix CEO Christian Behrenbruch stated, “We are very pleased to be working with Cyclotek to manufacture our products for the ANZ region. We’ve chosen to work with the Cyclotek team because of their experience, stellar track-record of delivering product and effective integration with both domestic and international clinical studies.”
Cyclotek Managing Director Greg Santamaria commented, “It’s great to see the emergence of a new radiopharmaceutical company with a late-stage product development pipeline that is committed to including Australian clinical sites in its development activities. We look forward to partnering with Telix for both clinical trials and ultimately the delivery of product to patients.”
The full press release can be found here.